OncoCyte Corporation (OCX)

2,7600 -0,1700 (-5,80%) Börsenschluss: 04:00PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://www.oncocyte.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 43

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Joshua Riggs	President, CEO & Director	504,63k	N/A	1983
Mr. James Liu	Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer	259,83k	N/A	1996
Dr. Ekkehard Schutz M.D., Ph.D.	Chief Science Officer	409,27k	N/A	N/A
Mr. Peter Hong	VP, General Counsel & Secretary	N/A	N/A	N/A
Mr. Yuh-Min Chiang Ph.D.	Senior Vice President of R&D and Product Development	N/A	N/A	N/A
Ms. Sandra O'Donald	Senior Vice President of Business Operations	N/A	N/A	N/A
Dr. Michael D. West Ph.D.	Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.	N/A	N/A	1953

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Corporate Governance

OncoCyte Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.